MUC13xMSLN

MUC13xMSLN appears to be an experimental bispecific antibody or T‑cell engager designed to simultaneously recognize the tumor-associated mucin Mucin 13 (MUC13) and Mesothelin (MSLN), two cell-surface glycoproteins frequently overexpressed in epithelial cancers. By co-targeting MUC13, which is implicated in cancer cell plasticity, EMT, and chemoresistance, and MSLN, a well-established solid tumor antigen, this construct is likely intended to enhance tumor selectivity and support immune-mediated killing of dual-positive cancer cells while sparing normal tissues that express only one antigen at low levels. No public clinical or preclinical dossier specifically describing MUC13xMSLN could be identified, suggesting it is at most in very early, preclinical concept or internal discovery stages.